<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02628847</url>
  </required_header>
  <id_info>
    <org_study_id>53515</org_study_id>
    <nct_id>NCT02628847</nct_id>
  </id_info>
  <brief_title>Sildenafil and Stroke Recovery</brief_title>
  <official_title>Sildenafil and Stroke Recovery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Utah</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Utah</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a small, pilot randomized clinical trial of administering sildenafil citrate to
      individuals within 10 days of ischemic stroke who have motor impairment and who are
      undergoing inpatient rehabilitation compared to placebo. The primary outcome is motor
      recovery at one and three months.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Individuals who are within 4-10 days post ischemic stroke with arm hemiparesis or hemiplegia
      who are admitted to inpatient rehabilitation are randomized to receive either sildenafil
      citrate (25 mg once per day) or placebo for 14 days. These individuals receive usual
      rehabilitation and medical care. Primary outcomes are motor skills and walking speed at one
      and three months.

      If willing and able, participants undergo an MRI to measure the integrity of the white matter
      pathways in the motor system using diffusion tensor imaging. Repeat MRIs are obtained at one
      and three months. The investigators will examine if such white matter integrity predicts
      response to the drug and if the drug facilitates changes in white matter.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Recruitment was problematic
  </why_stopped>
  <start_date>March 2012</start_date>
  <completion_date type="Actual">October 2016</completion_date>
  <primary_completion_date type="Actual">October 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fugl-Meyer Motor Assessment</measure>
    <time_frame>change from baseline at 1 month</time_frame>
    <description>An assessment of upper extremity and lower extremity motor impairment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Fugl-Meyer Assessment</measure>
    <time_frame>change from baseline at 3 months</time_frame>
    <description>An assessment of upper extremity and lower extremity motor impairment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>10 meter walk</measure>
    <time_frame>change from baseline at one month</time_frame>
    <description>an assessment of usual gait speed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Wolf Motor Function Test</measure>
    <time_frame>baseline, one month, three months</time_frame>
    <description>An assessment of motor function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Motor Activity Log</measure>
    <time_frame>one month</time_frame>
    <description>A self-report of paretic arm (frequency and perceived ability) use in every day activities</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke Impact Scale</measure>
    <time_frame>one month</time_frame>
    <description>A self-report measure of the impact of stroke on the individual for body functions, activities, and participation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>10 meter walk</measure>
    <time_frame>change from baseline at 3 months</time_frame>
    <description>an assessment of usual gait speed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Wolf Motor Function Test</measure>
    <time_frame>change from baseline at 3 months</time_frame>
    <description>An assessment of motor function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Motor Activity Log</measure>
    <time_frame>3 months</time_frame>
    <description>A self-report of paretic arm (frequency and perceived ability) use in every day</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke Impact Scale</measure>
    <time_frame>3 months</time_frame>
    <description>A self-report measure of the impact of stroke on the individual for body</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of participants with unsafe Blood pressure change</measure>
    <time_frame>one month</time_frame>
    <description>blood pressure reductions or increases while taking the drug/placebo</description>
  </other_outcome>
  <other_outcome>
    <measure>number of participants with cardiovascular side effects</measure>
    <time_frame>one month</time_frame>
    <description>cardiovascular events, such as heart attack, angina pectoris, heart failure</description>
  </other_outcome>
  <other_outcome>
    <measure>number of participants with visual side effects</measure>
    <time_frame>one month</time_frame>
    <description>new abnormal color vision, light sensitivity, blurred vision or other visual side effects</description>
  </other_outcome>
  <other_outcome>
    <measure>number of participants with auditory or vestibular side effects</measure>
    <time_frame>one month</time_frame>
    <description>new loss of hearing, tinnitus, dizziness</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Stroke</condition>
  <arm_group>
    <arm_group_label>Drug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sildenafil citrate 25mg once per day for 14 days starting day 5-9 post stroke while undergoing usual rehabilitation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo capsule once per day for 14 days starting day 5-9 post stroke while undergoing usual rehabilitation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sildenafil citrate</intervention_name>
    <arm_group_label>Drug</arm_group_label>
    <other_name>Viagra</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. between 4 and 9 days post-ischemic stroke;

          2. admitted to inpatient rehabilitation;

          3. cognitively able to provide consent or assent;

          4. were living independently in the community prior to their stroke.

        Exclusion Criteria:

          1. hemorrhagic stroke or subarachnoid hemorrhage;

          2. other neurological or psychiatric conditions deemed by the investigator to impair
             participation;

          3. no previous stroke on same side of brain unless that stroke was cerebellar

          4. moribound or not expected to live 6 months;

          5. contraindications to taking sildenafil in pill or syrup form;

          6. other medical conditions that would limit ability to participate in the study,
             specifically a) currently taking the P450 enzyme inhibitors (erythromycin,
             ketoconazole, itraconazole, saquinavir), b) currently taking the protease inhibitor
             ritonavir, c) currently taking nitrates or have a history of requiring nitrates
             treatment, d) have left ventricular outflow obstruction (i.e., aortic stenosis,
             idiopathic hypertrophic subaortic stenosis as confirmed by review of standard of care
             echo received before admission to rehabilitation), e) have severely impaired autonomic
             control of blood pressure, f) have previous history of symptomatic hypotension, g)
             have severely impaired hepatic function, h) is pregnant or become pregnant during the
             course of the study, i) Any medical condition which, in the opinion of the
             investigator, may compromise compliance with the objectives and/or procedures of the
             protocol.

          7. scores &gt; 50 on the upper extremity section of the Fugl-Meyer or no walking/gait
             impairment

             For the MRI portion of the study only:

          8. contraindication to MRI: ferrous metal in body, lead included body art,
             claustrophobia, pacemaker

          9. allergic to or had previous reaction to gadolinium
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lorie G Richards, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Utah</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Zhang RL, Chopp M, Roberts C, Wei M, Wang X, Liu X, Lu M, Zhang ZG. Sildenafil enhances neurogenesis and oligodendrogenesis in ischemic brain of middle-aged mouse. PLoS One. 2012;7(10):e48141. doi: 10.1371/journal.pone.0048141. Epub 2012 Oct 31.</citation>
    <PMID>23118941</PMID>
  </results_reference>
  <results_reference>
    <citation>Zhang L, Zhang RL, Wang Y, Zhang C, Zhang ZG, Meng H, Chopp M. Functional recovery in aged and young rats after embolic stroke: treatment with a phosphodiesterase type 5 inhibitor. Stroke. 2005 Apr;36(4):847-52. Epub 2005 Mar 3.</citation>
    <PMID>15746452</PMID>
  </results_reference>
  <results_reference>
    <citation>Zhang R, Wang Y, Zhang L, Zhang Z, Tsang W, Lu M, Zhang L, Chopp M. Sildenafil (Viagra) induces neurogenesis and promotes functional recovery after stroke in rats. Stroke. 2002 Nov;33(11):2675-80.</citation>
    <PMID>12411660</PMID>
  </results_reference>
  <results_reference>
    <citation>Li L, Jiang Q, Zhang L, Ding G, Gang Zhang Z, Li Q, Ewing JR, Lu M, Panda S, Ledbetter KA, Whitton PA, Chopp M. Angiogenesis and improved cerebral blood flow in the ischemic boundary area detected by MRI after administration of sildenafil to rats with embolic stroke. Brain Res. 2007 Feb 9;1132(1):185-92. Epub 2006 Dec 26.</citation>
    <PMID>17188664</PMID>
  </results_reference>
  <results_reference>
    <citation>Ding G, Jiang Q, Li L, Zhang L, Zhang ZG, Ledbetter KA, Gollapalli L, Panda S, Li Q, Ewing JR, Chopp M. Angiogenesis detected after embolic stroke in rat brain using magnetic resonance T2*WI. Stroke. 2008 May;39(5):1563-8. doi: 10.1161/STROKEAHA.107.502146. Epub 2008 Mar 20.</citation>
    <PMID>18356548</PMID>
  </results_reference>
  <results_reference>
    <citation>Ding G, Jiang Q, Li L, Zhang L, Zhang ZG, Ledbetter KA, Panda S, Davarani SP, Athiraman H, Li Q, Ewing JR, Chopp M. Magnetic resonance imaging investigation of axonal remodeling and angiogenesis after embolic stroke in sildenafil-treated rats. J Cereb Blood Flow Metab. 2008 Aug;28(8):1440-8. doi: 10.1038/jcbfm.2008.33. Epub 2008 Apr 16.</citation>
    <PMID>18418368</PMID>
  </results_reference>
  <results_reference>
    <citation>Ding G, Jiang Q, Li L, Zhang L, Zhang Z, Lu M, Li Q, Gu S, Ewing J, Chopp M. Longitudinal magnetic resonance imaging of sildenafil treatment of embolic stroke in aged rats. Stroke. 2011 Dec;42(12):3537-41. doi: 10.1161/STROKEAHA.111.622092. Epub 2011 Sep 8.</citation>
    <PMID>21903952</PMID>
  </results_reference>
  <results_reference>
    <citation>Silver B, McCarthy S, Lu M, Mitsias P, Russman AN, Katramados A, Morris DC, Lewandowski CA, Chopp M. Sildenafil treatment of subacute ischemic stroke: a safety study at 25-mg daily for 2 weeks. J Stroke Cerebrovasc Dis. 2009 Sep-Oct;18(5):381-3. doi: 10.1016/j.jstrokecerebrovasdis.2009.01.007.</citation>
    <PMID>19717023</PMID>
  </results_reference>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 7, 2015</study_first_submitted>
  <study_first_submitted_qc>December 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 11, 2015</study_first_posted>
  <last_update_submitted>January 3, 2017</last_update_submitted>
  <last_update_submitted_qc>January 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Utah</investigator_affiliation>
    <investigator_full_name>Lorie Richards</investigator_full_name>
    <investigator_title>Chair and Associate Professor</investigator_title>
  </responsible_party>
  <keyword>stroke</keyword>
  <keyword>rehabilitation</keyword>
  <keyword>motor skills</keyword>
  <keyword>sildenafil citrate</keyword>
  <keyword>White matter</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Citric Acid</mesh_term>
    <mesh_term>Sildenafil Citrate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

